This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Patients with histologically or cytologically proven metastatic PDAC
1st line treatment with NalIriFOx according to physician's choice
Patients willing to provide a Written Informed Consent
Patients not matching the above-mentioned inclusion criteria
Neoadjuvant or adjuvant treatment within 6 months from enrolment
Prior treatment with Liposomal irinotecan
Prior treatment of pancreatic cancer in the metastatic setting with chemotherapy or investigational therapy